DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for TCF12-related craniosynostosis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTCF12-related craniosynostosis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for tcf12-related craniosynostosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
TCF12 mutations are a known but uncommon genetic cause of coronal craniosynostosis. In a 2019 study of two Turkish patients, targeted next-generation sequencing identified two different truncating TCF12 variants: a known deletion (c.778_779delAT; p.Met260Valfs*5) and a novel deletion (c.1102_1108delTCACCTC; p.Pro369Glnfs*26). Both patients had coronal suture synostosis, and shared clinical features included bilateral simian crease and hidden cleft palate. A 2025 case report described a patient with bilateral coronal craniosynostosis carrying a novel heterozygous TCF12 splice-site mutation (NM_207037.2;intron16:c.1468-G>T) not found in either parent. That report noted a novel clinical feature associated with the mutation, but did not provide survival or response data.
The broader context of craniosynostosis genetics is that, as of a 2018 review, 57 human genes had been reported with causal mutations by 2015, with many more identified since. However, the overall frequency of a genetic diagnosis remains around 25%, and 70% of cases are classified as nonsyndromic. For TCF12 specifically, no drug treatment is described in any of these abstracts. Management is surgical: a 2014 prospective study of 85 children with craniosynostosis used 99mTc-ECD SPECT to assess cerebral perfusion. Preoperatively, regional perfusion abnormalities were seen in the hemisphere corresponding to the fused suture. Postoperatively, these defects disappeared in all cases, and the mean mental performance quotient (MPQ) increased significantly only in children whose perfusion defect resolved after surgery. That study did not stratify by TCF12 status.
What is missing for TCF12-related craniosynostosis is any drug-based intervention. No abstract reports a pharmacological therapy, repurposed or otherwise. The genetic basis is increasingly defined, but the condition remains one where surgical release is the only described intervention. There are no data on targeted molecular treatments, no clinical trials of any drug, and no evidence that any existing compound alters suture fusion or neurodevelopmental outcome in TCF12 mutation carriers. The missing elements are a druggable target, preclinical models for screening, and a trial design that could test a repurposed agent against a natural history that is still being characterised.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Molecular Syndromology · 2018 · 67 citations · open access
Genetic Causes of Craniosynostosis: An Update
AbstractIn 1993, Jabs et al. were the first to describe a genetic origin of craniosynostosis. Since this discovery, the genetic causes of the most common syndromes have been described. In 2015, a total of 57 human genes were reported for which there had been evidence that mutations were causally related to craniosynostosis. Facilitated by rapid technological developments, many others have been identified since then. Reviewing the literature, we characterize the most common craniosynostosis syndromes followed by a description of the novel causes that were identified between January 2015 and December 2017.
BioMed Research International · 2014 · 11 citations · open access
Role of<sup>99m</sup>Tc-ECD SPECT in the Management of Children with Craniosynostosis
AbstractPURPOSE OF THE REPORT: There is a paucity of data on correlation of various imaging modalities with clinical findings in craniosynostosis. Moreover, no study has specifically reported the role of (99m)Tc-ECD SPECT in a large number of subjects with craniosynostosis. MATERIALS AND METHODS: We prospectively analyzed a cohort of 85 patients with craniosynostosis from year 2007 to 2012. All patients underwent evaluation with (99m)Tc-ECD SPECT and the results were correlated with radiological and surgical findings. RESULTS: (99m)Tc-ECD SPECT revealed regional perfusion abnormalities in the cerebral hemisphere corresponding to the fused sutures preoperatively that disappeared postoperatively in all the cases. Corresponding to this, the mean mental performance quotient (MPQ) increased significantly (P < 0.05) postoperatively only in those children with absent perfusion defect postoperatively. CONCLUSIONS: Our study suggests that early surgery and release of craniosynostosis in patients with preoperative perfusion defects (absent on (99m)Tc-ECD SPECT study) are beneficial, as they lead to improved MPQ after surgery.
American Journal of Medical Genetics Part A · 2019 · 5 citations
Coronal craniosynostosis due to <i>TCF12</i> mutations in patients from Turkey
AbstractCraniosynostosis consists of premature fusion of one or more cranial sutures and can be seen as part of a syndrome or diagnosed as nonsyndromic (isolated). Although more than 180 craniosynostosis syndromes have been identified, 70% of the cases are diagnosed as nonsyndromic. On the other hand, genetic causes of the cases are mostly unknown and the overall frequency of the genetic diagnosis is around 25%. In this study, we used targeted Next Generation Sequencing (NGS) analysis to identify the genetic variations of two craniosynostosis cases. We have identified two different truncating mutations, a known NM_207036.1:c.778_779delAT;p.(Met260Valfs*5) and a novel NM_207036.1:c.1102_1108delTCACCTC;p.(Pro369Glnfs*26) TCF12 variants. Additionally, upon physical examination of these two cases, we have observed some shared clinical similarities as well as differences such as bilateral simian crease and hidden cleft palate. This is the first study that reports the TCF12 mutations in Turkish patients with coronal suture synostosis.
Journal of Craniofacial Surgery · 2025 · 2 citations
Extended Phenotype of Bilateral Coronal Craniosynostosis Due to Novel TCF12 Mutation
AbstractCraniosynostosis is the premature fusion of the cranial sutures, a heterogeneous disorder with a prevalence of ~1 in 2200. The etiology of craniosynostosis is largely unknown. However, several recent genomic discoveries have elucidated the genetic basis for nonsyndromic craniosynostosis, particularly unicoronal or bicoronal craniosynostosis. Coronal craniosynostosis is the second most common type after sagittal craniosynostosis. Here, the authors present a case of bilateral coronal craniosynostosis caused by a novel pathogenic variant of TCF12. The authors performed whole exome sequencing and found a heterozygous NM_207037.2;intron16:c.1468-G >T mutation in TCF12. The patient's parents did not carry this mutation. This report describes a novel feature associated with bilateral coronal craniosynostosis is described. Further reports and genetic research may deepen the authors' understanding of the genetic and clinical background of this disorder.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
